Pharmaceuticals News

Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with...

Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT2C) pharmacodynamics approved in its FDA product...

Agreement Grants Conba Rights for the Development and Commercialization of Cebranopadol for Pain Across Mainland China, Hong Kong, Macao and Taiwan, representing an important step in expanding the...

Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed. History...

SOTIO's ADC, SOT109, given Fast Track Designation for advanced unresectable or metastatic colorectal cancer who have exhausted standard treatment options.

WILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary...

SYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced...

Cannara signs first long-term international supply agreement with Curaleaf, accelerating Valleyfield expansion and entry into global medical markets.

MONTRÉAL, 14 juill. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous ») (TSX: LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement intégré de cannabis...

- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North...